Skip to main content
生物谷 logo

生物谷 — Investor Relations & Filings

Ticker · 920266 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2024-07-04 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920266

About 生物谷

https://www.bioon.com/

Bio-Valley specializes in the research, development, and manufacturing of botanical-based therapeutic solutions, with a primary focus on cardiovascular and cerebrovascular health. The company is a leader in the industrialization of Erigeron breviscapus (Dengzhanhua), a botanical resource used for treating ischemic stroke and its sequelae. Its core product portfolio includes Dengzhan Shengmai Capsules and Dengzhan Xixin Injection, which are utilized in clinical settings for their neuroprotective and microcirculation-improving properties. Bio-Valley maintains a comprehensive value chain encompassing botanical cultivation, standardized extraction, and large-scale production. By leveraging advanced extraction technologies and rigorous quality control, the company provides evidence-based solutions for chronic disease management and geriatric care.

Recent filings

Filing Released Lang Actions
独立董事提名人声明与承诺
Board/Management Information Classification · 95% confidence The document is a nomination statement and commitment declaration for independent director candidates for the company's board. It details the qualifications, independence criteria, and legal compliance of the nominees. There is no financial data, no report or results announcement, no meeting materials, no voting results, and no regulatory certification. The document is an announcement related to board/management changes, specifically the nomination of independent directors. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on nomination, not a full report or announcement of a report publication.
2024-07-04 Chinese
董事、监事换届的公告
Board/Management Information Classification · 100% confidence The document is titled as a "董事、监事换届公告" which translates to "Announcement of Board and Supervisory Committee Re-election". It details the nomination and appointment of new board members and supervisors, including their qualifications and backgrounds. The document discusses changes in the company's board of directors and supervisory board, the nomination process, and the impact of these changes on the company. There is no financial data, earnings information, or report publication mentioned. The document is an official announcement regarding changes in the company's board and senior management. Therefore, it fits the category of Board/Management Information (MANG). The document length is 4055 characters, which is consistent with an announcement rather than a full report.
2024-07-04 Chinese
独立董事候选人声明（孙继伟）
Board/Management Information Classification · 95% confidence The document is a declaration statement by an independent director candidate for a company's board, detailing qualifications, independence criteria, and compliance with regulatory requirements. It is not a financial report, earnings release, or any form of meeting presentation or voting result. It is a regulatory announcement related to board/management information but specifically about a candidate's declaration rather than an appointment or change announcement. Given the content, the best fitting category is Board/Management Information (MANG) as it relates to board candidate information and governance compliance.
2024-07-04 Chinese
第四届董事会第二十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 25th meeting of the 4th Board of Directors of Yunnan Biological Valley Pharmaceutical Co., Ltd. It includes information about the meeting's convening, attendance, and the approval of proposals related to the early re-election of the board and nomination of candidates for the 5th Board of Directors. It also discusses voting results and legal disputes regarding voting rights. The document is not a full annual or interim report, nor is it a financial statement or earnings release. It is not a proxy solicitation or AGM information but specifically concerns board-level decisions and changes. Therefore, it fits the category of Board/Management Information (MANG). The document length is under 5,000 characters but contains substantive content about board resolutions, not just an announcement of a report publication, so it is not RPA or RNS.
2024-07-04 Chinese
关于对北京证券交易所2023年年报问询函的回复
Regulatory Filings
2024-05-23 Chinese
2023年年度股东大会决议公告
AGM Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2023 Annual General Meeting (AGM) of Yunnan Shengwu Gu Pharmaceutical Co., Ltd. It includes information about the meeting date, attendance, agenda items, voting results, and legal opinions confirming the validity of the meeting. The content focuses on the decisions made during the AGM rather than the full annual report or financial statements themselves. It also references other announcements where the full annual report and other documents are published separately. The document length is over 6000 characters and contains substantive details about the AGM proceedings and resolutions, which fits the definition of AGM Information (AGM-R). It is not a report publication announcement or a regulatory filing, as it contains detailed meeting content and voting results, not just a notice or certification.
2024-05-21 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.